Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

402

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 1, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

HS-20105

Administered intravenously every 21 days.

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06144723 - Study of HS-20105 for Injection in Patients With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter